Atezolizumab is one of the first approved anti-PD-L1 for the treatment of UC and approval was extended subsequently for lung cancers, bladder carcinoma and triple-negative breast carcinoma, where it has shown efficacy and a favorable toxicity profile [119,120,121,122,123,124]. This evidence concerns the gene CD274 and lung cancer.